Gene therapy with plasmid IL-12 delivered by electroporation in patients with malignant melanoma: Results of first human Phase I trial

被引：2
|
作者：
Heller, R.
DeConti, R.
Messina, J.
Andrews, S.
Urbas, P.
Ugen, K.
Puleo, C.
Sondak, V.
Riker, A.
Daud, A.
机构：
[1] Univ S Florida, Tampa, FL USA
[2] Univ S Florida, Ctr Mol Delivey, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70345-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
340
引用
收藏
页码：106 / 106
页数：1
相关论文
共 50 条
  • [31] Immuno-gene therapy of human melanoma phase I/II clinical trial
    Mackiewicz, A
    RoseJohn, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 34 - 34
  • [32] Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients
    Crosby, Erika J.
    Nagata, Hiroshi
    Telli, Melinda L.
    Acharya, Chaitanya R.
    Wapnir, Irene
    Zablotsky, Kaitlin
    Browning, Erica
    Hermiz, Reneta
    Svenson, Lauren
    Bannavong, Donna
    Malloy, Kellie
    Canton, David A.
    Twitty, Chris G.
    Osada, Takuya
    Lyerly, Herbert Kim
    CANCER RESEARCH, 2021, 81 (04)
  • [33] IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors
    Zhu, Shiguo
    Lee, Dean Anthony
    Li, Shulin
    JOURNAL OF IMMUNOLOGY, 2010, 184 (05): : 2348 - 2354
  • [34] Gene therapy with IL-2 and IL-12 in murine B16F10 melanoma
    Komel, T.
    Bosnjak, M.
    Brezar, S. Kranjc
    Signori, E.
    De Robertis, M.
    Sersa, G.
    Cemazar, M.
    FEBS OPEN BIO, 2021, 11 : 408 - 408
  • [35] Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy
    Eslahi, NK
    Muller, S
    Nguyen, L
    Wilson, E
    Thull, N
    Rolland, A
    Pericle, F
    CANCER GENE THERAPY, 2001, 8 (01) : 55 - 62
  • [36] Molecular mechanism of tumor regression and toxicity elicited by local and systemic IL-12 electroporation gene therapy, respectively
    Li, SL
    Xia, XQ
    MOLECULAR THERAPY, 2003, 7 (05) : S273 - S273
  • [37] Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy
    Nima K Eslahi
    Susanne Muller
    Long Nguyen
    Elizabeth Wilson
    Nikki Thull
    Alain Rolland
    Federica Pericle
    Cancer Gene Therapy, 2001, 8 : 55 - 62
  • [38] Phase I Clinical Trial of M032, an IL-12 Expressing Oncolytic HSV-1, for Adult Patients With Recurrent Malignant Glioma
    Estevez-Ordonez, Dagoberto
    Stein, John
    Malekenia, Pedram
    Gallegos, Carlos
    Atchley, Travis
    Laskay, Nicholas M.
    Clements, Jennifer
    Leavenworth, Jianmei
    Riley, Kristen O.
    Lobbous, Mina
    Aban, Inmaculada
    Sorace, Ana
    Nabors, Burt
    Markert, James M.
    NEUROSURGERY, 2025, 71 : 70 - 70
  • [39] Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12
    Yang, SY
    Liu, H
    Zhang, JN
    DNA AND CELL BIOLOGY, 2004, 23 (06) : 381 - 389
  • [40] Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.
    Daud, Adil
    Algazi, Alain Patrick
    Ashworth, Michelle T.
    Fong, Lawrence
    Lewis, Jera
    Chan, Stephen E.
    Buljan, Michael
    Molina, Manuel Alberto
    Takamura, Kathryn Toshimi
    Diep, Tuan Tu
    Heller, Richard
    Pierce, Robert H.
    Bhatia, Shailender
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345